Prosight Management, LP 13F Portfolio

CIK 1617201 Filing since Q4 2017 Q3 2026 filed Nov 13, 2026
Holdings as of Sep 30, 2026, from the 13F filed Nov 13, 2026.

Portfolio Snapshot

32 positions · Q3 2026

Prosight Management, LP reported 32 positions worth $515.48M for the quarter ended Sep 30, 2026, down 9.0% on the prior quarter. It opened 9 new positions, added to 11, trimmed 12 and exited 12. Its largest holding is Lakefront Biotherapeutics NV at 11.5% of the portfolio.

Portfolio Value
$515.48M
-9.0% QoQ · +37.0% YoY
Positions
32
9 new · 12 sold out
Top 10 Concentration
70.6%
of portfolio value
Largest Position
LKFT 11.5%
Lakefront Biotherapeutics NV
Net Buying
-$30.83M
$142.27M bought · $173.10M sold
Turnover
26.3%
of the portfolio traded
Top Sector
Healthcare
98% of value
Track Record
35
quarters on file since Q4 2017

Portfolio Value & Positions

Value Positions

Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.

Sector Allocation

2 sectors
98.01%
Healthcare
Healthcare98.01%
Financial Services1.99%

Quarterly Buying & Selling

Bought Sold

Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.

Position Changes

How many positions were opened, added to, trimmed or closed each quarter.

Sector Allocation Over Time

Share of reported value in each sector at every quarter end.

HealthcareFinancial ServicesOtherReal EstateTechnologyIndustrials

Largest Buys

Q3 2026
Holding Change Change % Trade Value Weight
ABVX Abivax S.A. +269.4K +250.9% $26.68M 7.24%
PRVA Privia Health Group, Inc. +1.05M – $20.67M 4.01%
STTK Shattuck Labs, Inc. +1.69M +28.4% $11.53M 10.12%
DNLI Denali Therapeutics Inc. +550.7K – $11.38M 2.21%
PRAX Praxis Precision Medicines, Inc. +36.4K – $10.60M 2.06%
HQY Healthequity, Inc. +115.8K – $10.24M 1.99%
BBIO BridgeBio Pharma, Inc. +150.0K – $9.87M 1.91%
MLYS Mineralys Therapeutics, Inc. +350.2K +77.9% $8.80M 3.9%
HUM Humana Inc +22.0K – $8.39M 1.63%
ALKS Alkermes plc. +155.6K +39.5% $6.31M 4.32%

Largest Sells

Q3 2026
Holding Change Change % Trade Value Weight
BSX Boston Scientific Corp -720.3K -56.7% $31.44M 4.66%
VEEV Veeva Systems Inc -106.2K -100.0% $18.85M Exited
INSM INSMED Inc -137.5K -36.6% $15.70M 5.27%
ALNY Alnylam Pharmaceuticals, Inc. -61.1K -62.3% $15.07M 1.77%
JANX Janux Therapeutics, Inc. -861.3K -22.6% $14.88M 9.87%
ADCT ADC Therapeutics SA -7.42M -94.9% $9.06M 0.095%
KURA Kura Oncology, Inc. -747.0K -36.9% $8.00M 2.65%
ICUI Icu Medical Inc -51.0K -100.0% $7.48M Exited
SNDX Syndax Pharmaceuticals Inc -387.4K -32.3% $7.28M 2.96%
ISRG Intuitive Surgical Inc -17.0K -100.0% $6.76M Exited

New Positions

Q3 2026
Holding Shares Trade Value Weight
PRVA Privia Health Group, Inc. +1.05M $20.67M 4.01%
DNLI Denali Therapeutics Inc. +550.7K $11.38M 2.21%
PRAX Praxis Precision Medicines, Inc. +36.4K $10.60M 2.06%
HQY Healthequity, Inc. +115.8K $10.24M 1.99%
BBIO BridgeBio Pharma, Inc. +150.0K $9.87M 1.91%
HUM Humana Inc +22.0K $8.39M 1.63%
ENOV Enovis CORP +267.4K $4.89M 0.948%
QTRX Quanterix Corp +825.0K $3.06M 0.594%
GENB Generate Biomedicines, Inc. +144.8K $2.17M 0.422%

Closed Positions

Q3 2026
Holding Shares Sold Trade Value Prior Weight
VEEV Veeva Systems Inc -106.2K $18.85M 3.33%
ICUI Icu Medical Inc -51.0K $7.48M 1.32%
ISRG Intuitive Surgical Inc -17.0K $6.76M 1.19%
PRCT PROCEPT BioRobotics Corp -268.3K $6.06M 1.07%
WGS GeneDx Holdings Corp. -85.5K $5.87M 1.04%
OPCH Option Care Health, Inc. -270.7K $5.68M 1%
EBS Emergent BioSolutions Inc. -460.0K $3.85M 0.681%
PFE Pfizer Inc -135.4K $3.26M 0.576%
KIDS Orthopediatrics Corp -157.5K $3.01M 0.532%
TECX Tectonic Therapeutic, Inc. -39.7K $1.37M 0.241%
Holdings · Q3 2026

32 Positions

As ofSep 30, 2026
Value$515.48M
Top 1070.6%
Avg position$16.11M
# Activity
17 more holdings Create a free account to keep reading this institution’s full portfolio.
Showing 1–15 of 32 positions 13F filings on SEC EDGAR

Tip. Select a row to see that position’s full history at Prosight Management.

About Prosight Management, LP’s 13F Portfolio

What are Prosight Management, LP’s largest holdings?

As of its Q3 2026 13F filing, Prosight Management, LP’s five largest positions were Lakefront Biotherapeutics NV (LKFT) at 11.5%, Shattuck Labs, Inc. (STTK) at 10.1%, Janux Therapeutics, Inc. (JANX) at 9.9%, Nektar Therapeutics (NKTR) at 9.2%, Abivax S.A. (ABVX) at 7.2% of the reported portfolio.

How much is Prosight Management, LP’s portfolio worth?

Prosight Management, LP reported a 13F portfolio worth $515.48M across 32 positions for Q3 2026. That is down 9.0% from the previous quarter.

What did Prosight Management, LP buy in Q3 2026?

Its largest purchases by value were Abivax S.A. ($26.68M), Privia Health Group, Inc. ($20.67M), Shattuck Labs, Inc. ($11.53M). It opened 9 new positions.

What did Prosight Management, LP sell in Q3 2026?

Its largest sales by value were Boston Scientific Corp ($31.44M), Veeva Systems Inc ($18.85M), INSMED Inc ($15.70M). It exited 12 positions entirely.

Where does this data come from?

From the Form 13F-HR reports Prosight Management, LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.

Similar-Sized Institutions

by reported 13F value

13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.